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Monoallelic thyroid  
peroxidase gene mutation 
in a patient with congenital 
hypothyroidism with total 
iodide organification defect 
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em paciente com hipotireoidismo congênito com 
defeito total de incorporação de iodeto
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SUMMARY
The aim of this study was to identify the genetic defect of a patient with dyshormonogene-
tic congenital hypothyroidisms (CH) with total iodide organification defect (TIOD). A male 
child diagnosed with CH during neonatal screening. Laboratory tests confirmed the per-
manent and severe CH with TIOD (99% perchlorate release). The coding sequence of TPO, 
DUOX2, and DUOXA2 genes and 2957 base pairs (bp) of the TPO promoter were sequenced. 
Molecular analysis of patient’s DNA identified the heterozygous duplication GGCC 
(c.1186_1187insGGCC) in exon 8 of the TPO gene. No additional mutation was detected 
either in the TPO gene, TPO promoter, DUOX2 or DUOXA2 genes. We have described 
a patient with a clear TIOD causing severe goitrous CH due to a monoallelic TPO mutation. 
A plausible explanation for the association between an autosomal recessive disorder with a 
single TPO-mutated allele is the presence of monoallelic TPO expression. Arq Bras Endocrinol Metab. 
2010;54(8):732-7
SUMÁRIO
O objetivo deste estudo foi identificar defeitos genéticos em paciente com hipotireoidismo 
congênito (HC) por disormonogênese e defeito total de incorporação de iodeto (DIIT). Neonato 
do sexo masculino com HC diagnosticado pelo rastreamento neonatal. Exames clínicos e radio-
lógicos confirmaram que o paciente apresentava HC severo e permanente com DIIT (teste de 
perclorato: 99%). A região codificadora dos genes TPO, DUOX2, DUOXA2 e 2957 pares de bases 
(pb) do promotor de TPO foram sequenciados. No paciente foi identificada a duplicação em he-
terozigose GGCC no éxon 8 do gene TPO (c.1186_1187insGGCC). Nenhuma outra mutação 
foi localizada nos genes TPO, incluindo o promotor, DUOX2 ou DUOXA2. Descrevemos 
paciente com grave defeito de organificação de iodeto, provocando HC severo com bócio, em 
consequência de uma única mutação monoalélica no gene TPO. A expressão monoalélica no 
tecido tireoideano explicaria a associação de uma doen ça autossômica recessiva com uma 
única mutação monoalélica. Arq Bras Endocrinol Metab. 2010;54(8):732-7
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IntROdUctIOn
Congenital hypothyroidism (CH) is the most com-mon cause of preventable mental retardation with 
prevalence ranging from 1:2000 to 1:3000 newborns. 
In recent years prevalence has increased due to lower 
TSH cutoff values (10 mU/mL) used in the newborn 
screening programs (1).
Confirmatory biochemical exams associated with 
imaging and perchlorate tests are performed when the 
child reaches three years of age. The tests are conduct-
ed after four weeks of L-thyroxine withdrawal, when 
there is no risk of brain damage.
The most common cause of congenital hypothy-
roidism is thyroid dysgenesis (athyreosis, hemiagenesis, 
hypoplasia, and ectopia) seen in approximately 75% of 
the cases. Defects in thyroid hormone synthesis, or dys-
hormogenesis, accounts for 15%-20% of the cases and is 
caused by defects in genes involved in the thyroid-hor-
mone synthesis pathway (2). Mutations in thyroid per-
oxidase (TPO) are the most frequent genetic alterations 
in dyshormonogenesis, with prevalence of 1/40,000 
newborns (3). Mutations in thyroglobulin (TG) (4), 
sodium iodide symporter (NIS), pendrin (PDS), dual 
oxidase 2 (DUOX2) (5), dual oxidase maturation fac-
tor 2 (DUOXA2) (6), and iodotyrosine deiodinase 
(DEHAL1) (7) genes have been also identified in pa-
tients with dyshormonogenesis. 
TPO is a heme-containing enzyme localized on the 
apical membrane of the follicular cell. TPO catalyzes 
the iodination of tyrosine residues in thyroglobulin, and 
couples these residues to form thyroid hormones (8).
TPO mutations have been associated with total io-
dide organification defect (TIOD), where more than 
80% of iodide is discharged from the intrathyroidal io-
dide pool, indicating that the iodide that is taken up was 
not incorporated into the TG protein. Partial iodide or-
ganification defects are associated with iodide discharge 
levels of between 25% and 79% (9). More than 60 TPO 
gene mutations have been previously described. Link-
age studies have characterized the autosomal recessive 
mode of inheritance of TPO gene disorders (3).
The aim of this study was to identify the genetic defect 
of a patient with dyshormonogenetic CH and TIOD. 
SUBJEctS
The index patient is a boy who was diagnosed with CH 
during neonatal screening with serum TSH of 35.9 
μUI/mL. His parents were not consanguineous. He 
was started on a daily dose of L-thyroxine (12.5 mg/
kg) at 30 days of life. CH was confirmed at the age 
of 3 years, when the medication was suspended for 4 
weeks and laboratory tests showed: serum TSH: 635.3 
μUI/mL (reference value: 0.5 – 4.5 μUI/mL); total 
T4 (T4T): 1.0 μg/dL (reference value: 4 – 11 μg/dL), 
Free T4 (FT4): 0.1 ng/dL (reference value: 0.7 – 1.7 
ng/dL); TG: 129.6 ng/mL (reference value: 5 − 30 
ng/mL) and iodide discharge after perchlorate: 99% 
(reference value < 15%). The scintigraphy and ultra-
sound examinations indicated a heterogeneous eutopic, 
larger than normal thyroid gland. 
This study was approved by the Ethical Committee 
of the Hospital das Clínicas, University of São Paulo 
Medical School. Informed consent was obtained from 
the parents of the patient.
MEtHOdS
thyroid function tests
Serum Total T4 (TT4), free T4 (FT4), total T3, TSH, 
and TG levels were determined by electrochemilumi-
nescence immunoassay (Roche Corporation, India-
napolis, IN). Perchlorate discharge test was performed 
with 25 mCi of radiodine 131I administered orally and 
thyroid uptake was measured after 1 hour. At this point 
0.5 g of potassium perchlorate was orally administered 
and sequential uptakes were measured at 15-minute in-
tervals for an additional hour. The effect of perchlorate 
was expressed as a percentage of radioiodine uptake 
at 1 hour. Thyroid volume was calculated after echo-
graphic studies. Scintigraphy was performed with 131I.
dnA sequencing
Peripheral blood DNA from the patient, his parents 
and his brother was isolated by the sodium dodecyl 
sulfate/proteinase K method. The complete coding se-
quence of the human TPO gene, including splice sites 
and flanking intronic regions of each exon, was ampli-
fied using primers and conditions reported previously 
(9). A TPO promoter region of 2957 bp was also se-
quenced with specific primers (Table 1).
DNA sequencing of each amplified fragment was 
performed with a ABI 377 system (Applied Biosystems 
Corp., Foster City, CA) using the same TPO-specific 
primers used in the amplification step. The sequences 
were compared with those of the human TPO gene se-
quence (GeneID: 7173).
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table 1. Primers used to amplify 2957 bp of the TPO promoter
name Primer forward Primer reverse PcR  product size (bp)
ProTPO 1 5’ gcccctttttcacagggtat 3’ 5 ’AACTGCACTGCTGAGTA 3’ 375
ProTPO 2 5’ tgaggattgaggggagaatg 3’ 5’ ctctggccgaatgagttagg 3’ 342
ProTPO 3 5’ gaagcctttgcatcgtgttt 3’ 5’ cccaagcccctagttttctt 3’ 451
ProTPO 4 5’ aggatggctgaatcctcaga 3’ 5’ gacttggagcctcttcatgc 3’ 482
ProTPO 5 5’ cctagacgctggtgctctg 3’ 5’ ccagactcggtggctcatta 3’ 425
ProTPO 6 5’ gagacttttggcagcaaggt 3’ 5’ agctgttgggtgaagtccag 3’ 466
ProTPO 7 5’ ggctacaaaacgacctggag 3’ 5’ ccatgagcctccagaaactg 3’ 406
In order to amplify and sequence the coding region 
and intron-exon borders of the DUOX2 and DUOXA2 
gene we used the primers and conditions previously 
described (5,6). These sequences were compared with 
those of human DUOX2 and DUOXA2 (GeneID: 
50506 and GeneID: 405753, respectively).
A control group of 100 healthy subjects without 
thyroid disease was evaluated to determine whether the 
observed DNA substitutions were bona fide mutations 
or polymorphisms. All control subjects had normal FT4 
(0.7-1.5 ng/dL) and TSH levels (0.5-4.5 U/mL).
RESULtS
Screening for TPO gene mutations identified the known 
insertion of 4 base pairs GGCC in position 1186 of the 
cDNA (c.1186_1187insGGCC) (or in position 1227 of 
the DNA gene), in exon 8, which introduces a new stop 
codon in exon 9 (p.Ala396fsX472) (10). This mutation 
was present in a heterozygous form (Figure 1) and was 
the only mutation identified in the TPO gene. Polymor-
phisms were also found in the promoter, intronic and 
coding sequences of the TPO gene (Table 2).
The 33 exons of the DUOX2 gene were sequenced 
revealing only polymorphisms in this gene. These 
DUOX2 alterations were also found in more than 1% 
of the control subject’s DNAs (Table 3). The sequence 
analysis of DUOXA2 gene did not show sequence al-
terations in the patient’s DNA.
table 2. Polymorphisms identified in the promoter, intronic and coding 
sequences of the TPO gene of the patient reported in this study 
Region dnA position nucleotide change
Amino acid 
substitution
Promoter -1197 A/A -
Promoter -706 G/G -
Promoter -35 A/A -
Exon 1 16 A/A -
Exon 2 102 C/G -
Intron 4 +31 T/C -
Exon 7 859 G/T Ala257Ser
Exon 8 1207 G/T Ala373 Ser
Exon 8 1283 G/C Ser398Thr
Exon 11 2088 C/T -
Exon 12 2235 C/T -
Exon 12 2263 A/C Thr725Pro
Exon 15 2630 C/C Val847Ala  
Figure 1. Sequence chromatograms showing the heterozygous mutation 
(c.1186_1187insGGCC) in exon 8.
The c.1186_1187insGGCC mutation was not 
identified in his mother, stepfather or brother’s DNA. 
Polymorphism’s analysis confirmed that there was not 
genetic relation between the patient and the stepfather.
table 3. Polymorphisms identified within DUOX2 gene sequence
dnA position nucleotide change Amino acid substitution
413 C>T Pro100Leu
567
598
C>T 
G>A
Gly131Arg
-
633 C>T -
1461 G>C -
2033 A>G His678Arg
2102 G>A Arg701Gln
2281 G>A -
3200 C>T -
gIVS14 +65C>A - -
gIVS17+10C>T - -
gIVS25+15T>A - -
gIVS33+29G>T - -
c.1186_1187 insGGCC
↓
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dIScUSSIOn
TPO enzymatic activity is essential for thyroid hor-
monogenesis. Inactivating TPO mutations are the most 
frequent molecular basis for dyshormonogenetic con-
genital goitrous hypothyroidism due to iodide organi-
fication defect (3). 
The most frequently studied phenotype is the 
TIOD, characterized by iodide discharge after perchlo-
rate > 80%. Most affected patients present with severe 
and permanent hypothyroidism with mental retarda-
tion if not treated in the neonatal period. Discharge 
levels between 25% and 79% are denominated partial 
iodide organification defects (PIOD). The variety of 
clinical features in PIOD patients suggests that diverse 
mechanisms such as delayed or reduced activity of en-
zymes involved in hormonogenesis, or defects in iodine 
storage and release (11) may lead to PIOD. 
The established molecular basis of TIOD is either 
due to biallelic (homozygous or compound hetero-
zygous) inactivation mutations in the TPO gene, or 
biallelic inactivation mutations in the DUOX2 gene. 
Biallelic inactivation of DUOX2 results in a complete 
block of H2O2 generation, a relatively rare genotype 
(5). More frequent, are the inactivating mutations in 
the TPO gene resulting in a TIOD (3). 
Few studies have described cases of PIOD due 
to TPO biallelic mutations (9,12,13). Mutations in 
DUOX2 and DUOXA2 have also been reported in 
PIOD patients (5,6). Inactivating monoallelic DUOX2 
mutations have also been reported in relation to tran-
sient forms of relatively mild hypothyroidism (5). 
In this study we described a male child with severe 
congenital goitrous hypothyroidism and TIOD, extreme-
ly low serum FT4 and TT4 coexisting with very high lev-
els of serum TSH and TG. Moreover a high iodine uptake 
and 99% of iodide discharge after perchlorate confirmed 
the absence of organification of iodide. Molecular analysis 
of the patient’s DNA indicated presence of duplication of 
the tetranucleotide GGCC (c.1186_1187insGGCC) in 
exon 8 of the TPO gene, in heterozygous state. Interest-
ingly, this was the only mutation identified in the whole 
TPO coding region, in the intron-exon borders and in 
~3000bp of the TPO promoter. No additional mutation 
was found either in DUOX2 or DUOXA2 genes. 
This mutation has been previously identified in other 
Brazilian TIOD patients as well as in other reports (3). 
The resulting frameshift introduces a new stop codon 
in exon 9, which could result in a grossly truncated 
protein and promote a drastic reduction of TPO activ-
ity in the affected thyroid tissue (Figure 2) (10).
Cases with a typical TIOD phenotype and a single 
TPO-mutated allele have also been described. The fre-
quency of this phenomenon is unexpectedly high. It 
has been found in around 9% to 65% of the reported 
TIOD or PIOD patients of different geographic origin 
(9,14-18). In our experience, three out of four TIOD 
Brazilian patients and three out of six PIOD patients, 
all with TPO mutations, had only one mutant allele 
(data not shown). 
Genetic explanations for monoallelic TPO mutations 
in TIOD patients may be the presence of intronic muta-
tions creating an alternative splicing site or of mutations 
located in the distal promoter, more than 3000 bp up-
stream of the transcription initiation site. The presence 
of large gene deletions has also been advocated. Poly-
morphisms, however, both in the coding and noncod-
ing regions of TPO patient’s gene deny this possibility.
Other mechanisms that may explain our’s and oth-
er’s TIOD cases with a single TPO-mutated allele is the 
presence of monoallelic expression in the thyroid tissue, 
as has been shown by Fugazzola and cols. (18). This 
group reported one family with TIOD due to monoal-
lelic expression of a maternal mutant TPO allele in the 
thyroid tissue. 
In diploid eukaryotic organisms, there are three dif-
ferent classes of monoallelically expressed genes. One 
class is the autosomal imprinted genes whose monoal-
lelic expression is regulated in a parent-of-origin-specific 
manner. A second class is X-inactivated genes regulated 
by a random process. The third class is autosomal genes 
subject to random monoallelic expression (such as odor-
ant receptor, immunoglobulins, T-cell receptors, inter-
leukins, and natural killer cell receptors) (19). A recent 
study has shown that this last class of genes is relatively 
frequent. Using a general strategy for genome-wide 
analysis of monoallelic expression, Gimelbrant  and cols. 
(19) showed that ~ 5% to 10% of 4000 assessed autoso-
mal genes display random monoallelic transcription in 
human cells with stability in each clonal cell line.
Unusual regulatory mechanisms have been ob-
served for monoallelically expressed genes: e.g., DNA 
rearrangement and allele-specific DNA methylation for 
the immunoglobulin gene; a single enhancer associated 
with multiple odorant receptor gene promoters located 
on different chromosomes (19). Other transcriptional 
or post-transcriptional mechanisms may also be con-
sidered, such as alternative polyadenylation, chromatin 
remodeling, histone modifications, RNA edditing and 
microRNA regulation. 
TPO monoallelic mutation in hypothyroidism
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The mechanism resulting in monoallelic TPO ex-
pression may also be independent of parental origin. 
Fugazzola and cols. (18) detected the maternal mutant 
TPO allele expression associated to the lack of pater-
nal allele transcripts at the thyroid tissue level. In our 
study, despite the fact that we were not able to study 
the biological father’s DNA, the exclusive expression 
of the paternal mutated allele may be considered. The 
stochastic origin of monoallelic TPO expression may 
be also supported by the detection of the same mu-
tant TPO allele in the healthy mother and in her severe 
congenital hypothyroid daughter with TIOD (data not 
shown). This was the case of another patient studied in 
our laboratory with monoallelic TPO mutation associ-
ated with silencing of the paternal allele.  
In conclusion we have described a patient with 99% 
of iodide discharged after perchlorate with a clear or-
ganification defect causing severe congenital goitrous 
hypothyroidism due to a monoallelic TPO mutation 
(c.1186_1187insGGCC) in exon 8.
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